About: NanOlogy
Profile:
Posts by NanOlogy:
- ATS 2019 Poster: Enhanced Tumor Regression and Immune Cell Infiltration by Inhaled Submicron Particle Paclitaxel (May 21, 2019 - Presentations)
- NanOlogy to Present Preclinical Lung Cancer Study Showing Inhaled NanoPac® Resulted in Increased Tumor Regression and Immune Response (May 14, 2019 - NanOlogy Press Release)
- Drug Development Technology: NanOlogy Starts Enrollment in NanoDoce’s Phase I/II Trial (May 7, 2019 - NanOlogy in the News)
- Cancers 2019: Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts (May 3, 2019 - Publications)
- NanOlogy announces First Patient Enrolled in a Phase 1/2 Clinical Trial of NanoDoce® for Treatment of Bladder Cancer (April 12, 2019 - Home Page, NanOlogy Press Release)
- BIOCEO19 Video: Reshaping Tumor Microenvironments via Immunotherapies. Panel including Gere diZerega, MD, Chief Medical Officer of NanOlogy (February 24, 2019 - Home Page, Presentations)
- ASCO-GU19 Poster: Evaluation of Submicron Particle Docetaxel Directly Injected into Uro-Oncologic Xenografts (February 19, 2019 - Home Page, Presentations)
- NanOlogy to Present Positive Preclinical Data for NanoDoce® in Treatment of Uro-Oncologic Cancers at 2019 Genitourinary Cancers (ASCO-GU) Symposium (February 13, 2019 - NanOlogy Press Release)
- NanOlogy Chief Medical Officer on Panel to Discuss Next Wave of Innovation in IO Therapy at BIO CEO & Investor Conference (February 5, 2019 - NanOlogy Press Release)
- SABCS 2018 Poster: Phase 1/2 Study of Topical SOR007 for Cutaneous Metastases (January 15, 2019 - Presentations)
- NanOlogy Named to BioSpace Top 20 Life Science Startups to Watch in 2019 (January 11, 2019 - Home Page, NanOlogy in the News)
- Wuxi AppTec: Small Molecule Chemotherapy May Play a Big Role in Cancer Immunotherapy (November 6, 2018 - Home Page, NanOlogy in the News)
- Positive Preclinical Findings from Inhaled NanoPac® Lung Study Published in the Journal of Aerosol Medicine and Pulmonary Drug Delivery (October 30, 2018 - NanOlogy Press Release)
- Journal of Aerosol Medicine and Pulmonary Drug Delivery: Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPac®) in a Rodent Model (October 29, 2018 - Publications)
- DFB Soria Completes a Phase 2 Clinical Trial of Submicron Particle Paclitaxel Anhydrous Ointment for Actinic Keratosis (September 18, 2018 - NanOlogy Press Release, Soria)
- DFB Soria Completes a Phase 2 Clinical Trial of Submicron Particle Paclitaxel Anhydrous Ointment for Actinic Keratosis (September 18, 2018 - Uncategorized)
- Drug Development: Targeted Delivery of Submicron Particle Cancer Chemotherapy: Helping Shift the Immunotherapy Paradigm (August 29, 2018 - NanOlogy in the News)
- NanOlogy Adds Clinical Trial Sites for Phase 2 Clinical Trials of NanoPac® in Pancreatic Cancer and Pancreatic Mucinous Cysts (August 8, 2018 - NanOlogy Press Release)
